Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00424476
Registration number
NCT00424476
Ethics application status
Date submitted
17/01/2007
Date registered
19/01/2007
Titles & IDs
Public title
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Query!
Scientific title
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Wk Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE)
Query!
Secondary ID [1]
0
0
BLISS-52
Query!
Secondary ID [2]
0
0
HGS1006-C1057
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
BLISS-52
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Systemic Lupus Erythematosus
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Placebo
Treatment: Drugs - Belimumab 1 mg/kg
Treatment: Drugs - Belimumab 10 mg/kg
Placebo comparator: Placebo - Placebo
Experimental: Belimumab 1 mg/kg - Belimumab 1 mg/kg
Experimental: Belimumab 10 mg/kg - Belimumab 10 mg/kg
Treatment: Drugs: Placebo
Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Treatment: Drugs: Belimumab 1 mg/kg
Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Treatment: Drugs: Belimumab 10 mg/kg
Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
SLE Responder Index (SRI) Response Rate at Week 52
Query!
Assessment method [1]
0
0
Percentage of subjects with a = 4 point reduction from baseline in SELENA SLEDAI score, and no worsening (increase of \< 0.30 points from baseline) in PGA, and no new BILAG A organ domain score or 2 new BILAG B organ domain scores compared with baseline.
SELENA SLEDAI is calculated from 24 individual descriptors; 0 indicates inactive disease and the maximum theoretical score is 105; scores \> 20 are rare. PGA is a visual analog scale scored from 0 to 3 (1=mild, 2=moderate, 3=severe). BILAG uses a single score for each of the 8 organ domains; range is from severe to no disease (A to E).
Query!
Timepoint [1]
0
0
Baseline, 52 weeks
Query!
Secondary outcome [1]
0
0
Percent of Subjects With a = 4 Point Reduction From Baseline in SELENA SLEDAI Score at Wk 52.
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Baseline, 52 weeks
Query!
Secondary outcome [2]
0
0
Mean Change in Physician's Global Assessment (PGA) at Wk 24.
Query!
Assessment method [2]
0
0
The PGA is a visual analog scale scored from 0 to 3. A score of 1 corresponds to mild lupus disease activity. A score of 2 correlates with moderate disease activity and a score of 3 with severe disease activity.
Query!
Timepoint [2]
0
0
Baseline, 24 weeks
Query!
Secondary outcome [3]
0
0
Mean Change From Baseline in Medical Outcomes 36-Item Short Form Health Survey (SF-36) Physical Component Summary Score (PCS) at Wk 24.
Query!
Assessment method [3]
0
0
The SF-36 is a generic health related quality of life (HRQOL) measurement. The survey includes 36 questions grouped to 8 domains and 2 summary measures (physical and mental health component, PCS and MCS, respectively) assessing HRQOL. Responses are scored according to the SF-36v2™ manual. A score is calculated for each SF-36 domain based on the patient's response to each question within it. This is then transformed to a scale ranging from 0 (worst) to 100 (best) points. The PCS is norm-based where the mean=50 and standard deviation (SD)=10. Higher scores represent better physical health.
Query!
Timepoint [3]
0
0
Baseline, 24 weeks
Query!
Secondary outcome [4]
0
0
Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by = 25% From Baseline to = 7.5 mg/Day During Weeks 40 Through 52
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Baseline, Weeks 40 through 52
Query!
Eligibility
Key inclusion criteria
Key
* Clinical diagnosis of SLE by ACR criteria.
* Active SLE disease.
* Autoantibody-positive.
* On stable SLE treatment regimen.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Pregnant or nursing
* Have received treatment with any B cell targeted therapy.
* Have received treatment with a biological investigational agent in the past year.
* Have received IV cyclophosphamide within 180 days of Day 0.
* Have severe lupus kidney disease.
* Have active central nervous system (CNS) lupus.
* Have required management of acute or chronic infections within the past 60 days.
* Have current drug or alcohol abuse or dependence.
* Have a historically positive test or test positive at screening for HIV, hepatitis B, or hepatitis C.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/05/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2010
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
865
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Repatriation Hospital - Daw Park
Query!
Recruitment hospital [2]
0
0
Emeritus Research, Cabrini Hospital - Melbourne
Query!
Recruitment hospital [3]
0
0
Monash Medical Centre - Melbourne
Query!
Recruitment hospital [4]
0
0
Royal Perth Hospital - Shenton Park
Query!
Recruitment postcode(s) [1]
0
0
5041 - Daw Park
Query!
Recruitment postcode(s) [2]
0
0
3144 - Melbourne
Query!
Recruitment postcode(s) [3]
0
0
3168 - Melbourne
Query!
Recruitment postcode(s) [4]
0
0
6008 - Shenton Park
Query!
Recruitment outside Australia
Country [1]
0
0
Argentina
Query!
State/province [1]
0
0
Buenos Aires
Query!
Country [2]
0
0
Argentina
Query!
State/province [2]
0
0
Ciudad Autonoma de Buenos Aires
Query!
Country [3]
0
0
Argentina
Query!
State/province [3]
0
0
La Plata
Query!
Country [4]
0
0
Argentina
Query!
State/province [4]
0
0
Rosario
Query!
Country [5]
0
0
Argentina
Query!
State/province [5]
0
0
San Miguel de Tucuman
Query!
Country [6]
0
0
Brazil
Query!
State/province [6]
0
0
Campinas
Query!
Country [7]
0
0
Brazil
Query!
State/province [7]
0
0
Curitiba
Query!
Country [8]
0
0
Brazil
Query!
State/province [8]
0
0
Fortaleza
Query!
Country [9]
0
0
Brazil
Query!
State/province [9]
0
0
Goiânia
Query!
Country [10]
0
0
Brazil
Query!
State/province [10]
0
0
Juiz de Fora
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
Porto Alegre
Query!
Country [12]
0
0
Brazil
Query!
State/province [12]
0
0
Rio de Janeiro
Query!
Country [13]
0
0
Brazil
Query!
State/province [13]
0
0
Salvador
Query!
Country [14]
0
0
Brazil
Query!
State/province [14]
0
0
São Paulo
Query!
Country [15]
0
0
Chile
Query!
State/province [15]
0
0
Santiago
Query!
Country [16]
0
0
Chile
Query!
State/province [16]
0
0
Viña del Mar
Query!
Country [17]
0
0
Colombia
Query!
State/province [17]
0
0
Cundinamarca
Query!
Country [18]
0
0
Colombia
Query!
State/province [18]
0
0
Santander
Query!
Country [19]
0
0
Colombia
Query!
State/province [19]
0
0
Barranquilla
Query!
Country [20]
0
0
Colombia
Query!
State/province [20]
0
0
Bogota
Query!
Country [21]
0
0
Colombia
Query!
State/province [21]
0
0
Bogotá
Query!
Country [22]
0
0
Colombia
Query!
State/province [22]
0
0
Bucaramanga
Query!
Country [23]
0
0
Colombia
Query!
State/province [23]
0
0
Medellín
Query!
Country [24]
0
0
Hong Kong
Query!
State/province [24]
0
0
Chai Wan
Query!
Country [25]
0
0
Hong Kong
Query!
State/province [25]
0
0
Shatin
Query!
Country [26]
0
0
Hong Kong
Query!
State/province [26]
0
0
Tuen Mun
Query!
Country [27]
0
0
India
Query!
State/province [27]
0
0
Bangalore
Query!
Country [28]
0
0
India
Query!
State/province [28]
0
0
Hyderabaad
Query!
Country [29]
0
0
India
Query!
State/province [29]
0
0
Hyderabad
Query!
Country [30]
0
0
India
Query!
State/province [30]
0
0
Lucknow
Query!
Country [31]
0
0
India
Query!
State/province [31]
0
0
Mumbai
Query!
Country [32]
0
0
India
Query!
State/province [32]
0
0
Trivandrum
Query!
Country [33]
0
0
Korea, Republic of
Query!
State/province [33]
0
0
Daegu
Query!
Country [34]
0
0
Korea, Republic of
Query!
State/province [34]
0
0
Daejeon
Query!
Country [35]
0
0
Korea, Republic of
Query!
State/province [35]
0
0
Inchon
Query!
Country [36]
0
0
Korea, Republic of
Query!
State/province [36]
0
0
Pusan
Query!
Country [37]
0
0
Korea, Republic of
Query!
State/province [37]
0
0
Seoul
Query!
Country [38]
0
0
Korea, Republic of
Query!
State/province [38]
0
0
Suwon
Query!
Country [39]
0
0
Peru
Query!
State/province [39]
0
0
Lima
Query!
Country [40]
0
0
Philippines
Query!
State/province [40]
0
0
Cebu City
Query!
Country [41]
0
0
Philippines
Query!
State/province [41]
0
0
Davao City
Query!
Country [42]
0
0
Philippines
Query!
State/province [42]
0
0
Las Pinas City
Query!
Country [43]
0
0
Philippines
Query!
State/province [43]
0
0
Manila City
Query!
Country [44]
0
0
Philippines
Query!
State/province [44]
0
0
Quezon City
Query!
Country [45]
0
0
Romania
Query!
State/province [45]
0
0
Bucharest
Query!
Country [46]
0
0
Romania
Query!
State/province [46]
0
0
Cluj Napoca
Query!
Country [47]
0
0
Russian Federation
Query!
State/province [47]
0
0
Moscow
Query!
Country [48]
0
0
Russian Federation
Query!
State/province [48]
0
0
St. Petersburg
Query!
Country [49]
0
0
Russian Federation
Query!
State/province [49]
0
0
St.-Petersburg
Query!
Country [50]
0
0
Russian Federation
Query!
State/province [50]
0
0
Yaroslavl
Query!
Country [51]
0
0
Taiwan
Query!
State/province [51]
0
0
Chia-Yi
Query!
Country [52]
0
0
Taiwan
Query!
State/province [52]
0
0
Haulien
Query!
Country [53]
0
0
Taiwan
Query!
State/province [53]
0
0
Kaohsiung
Query!
Country [54]
0
0
Taiwan
Query!
State/province [54]
0
0
Kaosiung
Query!
Country [55]
0
0
Taiwan
Query!
State/province [55]
0
0
Keelung
Query!
Country [56]
0
0
Taiwan
Query!
State/province [56]
0
0
Taichung
Query!
Country [57]
0
0
Taiwan
Query!
State/province [57]
0
0
Taipei
Query!
Country [58]
0
0
Taiwan
Query!
State/province [58]
0
0
Tau-Yuan County
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Human Genome Sciences Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
GlaxoSmithKline
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00424476
Query!
Trial related presentations / publications
Gupta SV, Fanget MC, MacLauchlin C, Clausen VA, Li J, Cloutier D, Shen L, Robbie GJ, Mogalian E. Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection. Drugs R D. 2021 Dec;21(4):455-465. doi: 10.1007/s40268-021-00369-w. Epub 2021 Nov 6. Zhou X, Lee TI, Zhu M, Ma P. Prediction of Belimumab Pharmacokinetics in Chinese Pediatric Patients with Systemic Lupus Erythematosus. Drugs R D. 2021 Dec;21(4):407-417. doi: 10.1007/s40268-021-00363-2. Epub 2021 Oct 9. Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison. RMD Open. 2021 Sep;7(3):e001747. doi: 10.1136/rmdopen-2021-001747. Rendas-Baum R, Baranwal N, Joshi AV, Park J, Kosinski M. Psychometric properties of FACIT-Fatigue in systemic lupus erythematosus: a pooled analysis of three phase 3 randomised, double-blind, parallel-group controlled studies (BLISS-SC, BLISS-52, BLISS-76). J Patient Rep Outcomes. 2021 Apr 8;5(1):33. doi: 10.1186/s41687-021-00298-x. Maslen T, Bruce IN, D'Cruz D, Ianosev M, Bass DL, Wilkinson C, Roth DA. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme. Lupus Sci Med. 2021 Feb;8(1):e000459. doi: 10.1136/lupus-2020-000459. Gomez A, Hani Butrus F, Johansson P, Akerstrom E, Soukka S, Emamikia S, Enman Y, Pettersson S, Parodis I. Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2021 Mar 2;60(3):1260-1272. doi: 10.1093/rheumatology/keaa453. van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, Fettiplace J, Wang ML, Ji B, Roth D. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension. Rheumatology (Oxford). 2020 Feb 1;59(2):281-291. doi: 10.1093/rheumatology/kez279. Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups. Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. Lupus Sci Med. 2014 Jun 26;1(1):e000031. doi: 10.1136/lupus-2014-000031. eCollection 2014. Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995. Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, Zhong ZJ, Clarke AE; BLISS-52 and -76 Study Groups. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. Ann Rheum Dis. 2014 May;73(5):838-44. doi: 10.1136/annrheumdis-2012-202865. Epub 2013 Mar 22. Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R; BLISS-52 and -76, and LBSL02 Study Groups. Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus. Lupus. 2013 Feb;22(2):144-54. doi: 10.1177/0961203312469259. Epub 2012 Dec 4. van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012 Aug;71(8):1343-9. doi: 10.1136/annrheumdis-2011-200937. Epub 2012 Feb 15. Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Jul;64(7):2328-37. doi: 10.1002/art.34400. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, Leon MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
Human Genome Sciences Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Query!
When will data be available (start and end dates)?
Query!
Available to whom?
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00424476